How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Allogeneic Stem Cell Transplantation Market
- By Stem Cell Source: Bone Marrow, Peripheral Blood Stem Cells (PBSC), Umbilical Cord Blood
- By Donor Type: Matched Related Donor (MRD), Matched Unrelated Donor (MUD), Haploidentical Donor, Cord Blood Donor
- By Indication: Hematologic Malignancies, Bone Marrow Failure Syndromes, Inherited Immune Disorders, Metabolic Disorders
- By Conditioning Regimen: Myeloablative Conditioning, Reduced-Intensity Conditioning (RIC), Non-Myeloablative Conditioning
- By Graft-versus-Host Disease (GVHD) Prophylaxis: Calcineurin Inhibitors, Post-Transplant Cyclophosphamide, Anti-Thymocyte Globulin (ATG), Methotrexate
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Bone Marrow leads By Stem Cell Source at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Allogeneic Stem Cell Transplantation Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Stem Cell Source 3
Donor Type 4
Indication 4
Conditioning Regimen 3
Graft-versus-Host Disease (GVHD) Prophylaxis 4
Companies profiled
Fresenius SE & Co. KGaA
Thermo Fisher Scientific Inc.
Miltenyi Biotec
Stemcell Technologies
Lonza Group AG
GE Healthcare
BD (Becton
Dickinson and Company)
Macopharma
NantKwest Inc.
CellGenix GmbH
Cytiva (part of Danaher Corporation)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius SE & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Stemcell Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GE Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Macopharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →NantKwest Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →CellGenix GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cytiva (part of Danaher Corporation)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AlloVir Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Kiadis Pharma (Sanofi)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Fate Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Gamida Cell Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,436M by 2033 · 10.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bone Marrow58.1
- Peripheral Blood Stem Cells (PBSC)27.2
- Umbilical Cord Blood14.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,104M → $2,424M · 10.3%
Europe$769.6M → $1,637M · 9.9%
Asia Pacific$702.7M → $1,592M · 10.8%
Latin America$435.0M → $1,072M · 11.9%
Middle East and Africa$334.6M → $828.7M · 12.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.442026
10.462027
10.472028
10.502029
10.502030
10.502031
10.522032
10.522033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius SE & Co. KGaA30.2
- Thermo Fisher Scientific Inc.14.7
- Miltenyi Biotec5.0
- Stemcell Technologies8.7
- Lonza Group AG5.5
- GE Healthcare7.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Stem Cell Source11.5%
Donor Type18.1%
Indication28.8%
Conditioning Regimen21.7%
Graft-versus-Host Disease (GVHD) Prophylaxis19.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe21.7
- Asia Pacific21.1
- Latin America14.2
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | 85 | 86 | 98 | 89 | 93 | 94 | 91 |
| Thermo Fisher Scientific Inc. | 72 | 78 | 78 | 68 | 69 | 70 | 73 |
| Miltenyi Biotec | 65 | 62 | 63 | 79 | 80 | 85 | 72 |
| Stemcell Technologies | 68 | 65 | 76 | 60 | 67 | 72 | 68 |
| Lonza Group AG | 60 | 51 | 61 | 54 | 63 | 57 | 58 |
| GE Healthcare | 68 | 49 | 62 | 47 | 46 | 47 | 53 |
| BD (Becton | 64 | 48 | 45 | 47 | 55 | 58 | 53 |
| Dickinson and Company) | 57 | 58 | 60 | 49 | 36 | 40 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius SE & Co. KGaA
- Thermo Fisher Scientific Inc.
- Miltenyi Biotec
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | − | ◐ | ◐ | ◐ | ✓ | ◐ |
| Miltenyi Biotec | − | ✓ | ◐ | ✓ | ◐ | ✓ |
| Stemcell Technologies | ✓ | − | ◐ | − | ◐ | − |
| Lonza Group AG | ◐ | − | − | − | ◐ | − |
| GE Healthcare | − | − | ◐ | ◐ | − | − |
| BD (Becton | ◐ | − | − | − | ◐ | ◐ |
| Dickinson and Company) | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius SE & Co. KGaA91
2Thermo Fisher Scientific Inc.73
3Miltenyi Biotec72
4Stemcell Technologies68
5Lonza Group AG58
6GE Healthcare53
7BD (Becton53
8Dickinson and Company)50
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Fresenius SE & Co. KGaA
Challenger3
Strong scale, closing on the leaders.
Thermo Fisher Scientific Inc.Miltenyi BiotecStemcell Technologies
Contender1
Focused players with pockets of strength.
Lonza Group AG
Niche3
Specialists in a single segment or region.
GE HealthcareBD (BectonDickinson and Company)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Stem Cell Source in North America, then scale across Allogeneic Stem Cell Transplantation Market — a $198M beachhead inside a $3.49B market.
Beachhead (SOM)$198Mobtainable near-term
Serviceable (SAM)$1.24Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Bone Marrow
Best fit — highest urgency & budget in Stem Cell Source.
Economic buyer76 fit
Peripheral Blood Stem Cells (PBSC)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Umbilical Cord Blood
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Stem Cell Source in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Donor Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel30%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Stem Cell Source leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Allogeneic Stem Cell Transplantation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified21%
Evaluation14%
Closed-won5%
$10.7KCAC
$47KLTV
4.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Allogeneic Stem Cell Transplantation Market is a resilient opportunity — $4.89B by 2033, compounding at 3.9%.
TAM · 2025$3.61Btoday
TAM · 2033$4.89Bforecast
CAGR3.9%2027–2033
Cumulative$38.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.89BTotal addressable market
SAM$1.97BServiceable available market
SOM$425MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Stem Cell Source.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Stem Cell Source moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.89BLarge & growingTAM by 2033 at 3.9% CAGR
$1.97BServiceable nowreachable with today’s model
$425MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.81BBear2.5% CAGR
$4.89BBase3.9% CAGR
$6.26BBull5.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Donor Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Allogeneic Stem Cell Transplantation Market — a $5.77B market by 2033. Plan: grow share from 8.0% to 13.3%.
Market size · 2033$5.77Btotal addressable
Market CAGR11.3%2027–2033
Target share13.3%from 8.0% today
Revenue ambition$768Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 13.3% | On track |
| Revenue | $491M | $768M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 35.8% | 40.5% | On track |
| Customer retention | 87.3% | 93.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Stem Cell Source
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Donor Type capability
A defensible second engine — invest in Donor Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Stem Cell Source share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Donor Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in Donor Type
- Authorise North America expansion plan
- Fund R&D program for Stem Cell Source leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Allogeneic Stem Cell Transplantation Market conversation — a $8.86B market you can size, segment and defend in minutes.
Market size · 2033$8.86Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers1,673+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Stem Cell Source
Goal Grow share in Stem Cell Source
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 3 mopayback period
$49K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Fresenius SE & Co. KGaAThermo Fisher Scientific Inc.Miltenyi BiotecStemcell TechnologiesLonza Group AGGE HealthcareBD (BectonDickinson and Company)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Allogeneic Stem Cell Transplantation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Allogeneic Stem Cell Transplantation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Digital PCR Instrument Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportAllogeneic Stem Cell Therapy Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDesmopressin Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAllogeneic Stem Cells Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportDesmopressin Acetate Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAllogeneic Human Chondrocyte Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDaunorubicin Hydrochloride (CAS 23541-50-6) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAllogeneic Bone Implant Materials Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAllogeneic Bone Graft Substitutes Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportKidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAllogeneic Bone Graft Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCinacalcet Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.